

Liste der bewilligten Forschungsprojekte 2023

Liste des projets de recherche acceptés en 2023

Basic research

Bastings Maartje | Rewiring the spatial organisation of key checkpoint molecules to reverse the immuno-suppressive state of cancer

Materials and Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne

CHF 369 988 | 48 months | KFS-5935-08-2023

Bentires-Alj Mohamed | Effect of risk factors and preventive strategies on breast tumour dormancy

Departement Biomedizin, Universitätsspital Basel, Basel

CHF 375 000 | 36 months | KFS-5765-02-2023

Brisken Cathrin | The role of androgen receptor signalling in the human breast epithelium: can anti-androgenic progestins prevent breast cancer?

SV ISREC UPBRI, EPF de Lausanne, Lausanne

CHF 369 800 | 36 months | KFS-5771-02-2023

Cafilich Amedeo | Targeting the m6A-RNA epitranscriptomic mark as a novel therapy for blood cancer

Biochemistry, University of Zurich, Zürich

CHF 374 800 | 36 months | KFS-5748-02-2023

Cavalli Andrea | Discovery and optimization of WWP1 inhibitors as new anti-prostate-cancer drugs

Computational Structural Biology, Institute for Research in Biomedicine (IRB), Bellinzona

CHF 208 250 | 36 months | KFS-5777-02-2023

Modena Mario Matteo | Bidirectional interactions of glioma and neural cells: investigating glioma cells integration into brain networks and modulation of brain activity

Biosystems Science and Engineering, ETH Zürich, Basel

CHF 301 988 | 48 months | KFS-5959-08-2023

Münz Christian | Targeting the human oncogenic Kaposi sarcoma associate herpesvirus (KSHV) via its gene products and specific T cell responses

Institut für Experimentelle Immunologie, Universität Zürich (UZH), Zürich

CHF 375 000 | 36 months | KFS-5896-08-2023

Platt Randall | Systematic functional interrogation of clinical variants of uncertain significance using precision gene editing

Department of Biosystems Science and Engineering, ETH Zürich, Basel

CHF 375 000 | 36 months | KFS-5736-02-2023

Scheiermann Christoph | Circadian dynamics in tumour infiltrating leukocyte (TIL) fate and phenotype

Département de Pathologie et Immunologie, Université de Genève (UNIGE), Genève

CHF 374 997 | 36 months | KFS-5898-08-2023

Sendoel Ataman | Single-cell CRISPR to characterize small open reading frames in cancer

Institute for Regenerative Medicine, University of Zurich, Schlieren-Zurich

CHF 250 000 | 24 months | KFS-5730-02-2023

Standfuss Joerg | A molecular view of melanoma-associated BRAF kinase dynamics

Laboratory of Biomolecular Research, Paul Scherrer Institut (PSI), Villigen PSI

CHF 371 600 | 48 months | KFS-5737-02-2023

Thomä Nicolas | Tuning nuclear receptor activation & degradation for therapeutic benefit in cancer

Genome Regulation, Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

CHF 374 990 | 36 months | KFS-5933-08-2023

Trono Didier | Targeting the human-restricted oncogene POU5F1B for precision oncology

Global Health Institute, EPF de Lausanne, Lausanne

CHF 374 500 | 36 months | KFS-5823-02-2023

Vallelian Florence | Haemorrhage-induced NRF2 signalling in tumour-associated macrophages drives cancer growth, invasion, and immunotherapy resistance

Internal medicine, University Hospital Zurich, Zurich

CHF 374 750 | 36 months | KFS-5944-08-2023

Verdeil Gregory | Mechanisms regulating NFAT5 dependent inhibition of anti-tumour response in exhausted CD8 T-cells

Oncologie fondamentale, Université de Lausanne (UNIL), Epalinges

CHF 370 100 | 36 months | KFS-5770-02-2023

von Gunten Stephan | PILRalpha glyco-immune checkpoints in cancer

Institut für Pharmakologie, Universität Bern, Bern

CHF 375 000 | 36 months | KFS-5936-08-2023

Vozenin Marie-Catherine | Understanding how FLASH radiotherapy works: investigating the transcriptional and Wnt dependency of FLASH in zebrafish embryo

Service de Radio-Oncologie, Hôpitaux universitaires de Genève (HUG), Geneva

CHF 366 600 | 36 months | KFS-5757-02-2023

Epidemiological research

Krieger Jean-Philippe | Do vagal inputs to the stomach promote gastric cancer incidence in humans? A nationwide cohort study to bridge the gap between preclinical studies and therapeutic applications

Institute of Veterinary Pharmacology and Toxicology, University of Zurich, Zurich
CHF 196 350 | 36 months | KFS-5745-02-2023

Rohrman Sabine | Impact of COVID-19 pandemic on cancer diagnosis and case stage distribution in the cantons of Zurich and Zug

Abteilung Epidemiologie Chronischer Krankheiten, Institut für Epidemiologie, Biostatistik und Prävention (EBPI), Zürich
CHF 117 900 | 24 months | KFS-5731-02-2023

Clinical Research – laboratory-oriented

Fix Michael | Unlocking new frontiers in radiotherapy: treatment planning for very high-energy electron therapy

Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital Bern, Bern
CHF 239 041 | 24 months | KFS-5948-08-2023

Hartmann Karin | Investigation of the immune milieu in mastocytosis to explore novel treatment options

Department of Biomedicine, University Hospital Basel, Basel
CHF 357 318 | 36 months | KFS-5979-08-2023

Le Magnen Clementine | Investigating the role of glucocorticoid receptor signalling in cellular plasticity and bladder cancer progression

Department of Biomedicine, Institute of Pathology, and Department of Urology, University Hospital Basel, Basel
CHF 317 627 | 48 months | KFS-5996-08-2023

Levesque Mitchell | Multi-modal single cell analysis of primary and metastatic uveal melanoma

Dermatology, University of Zurich, Schlieren
CHF 370 500 | 42 months | KFS-5785-02-2023

McKee Thomas | Genomic and clinical characterization of responders to PARP inhibitors in ovarian cancer

Service de Pathologie Clinique, Hôpitaux universitaires de Genève (HUG), Genève
CHF 304 395 | 36 months | KFS-5977-08-2023

Rubin Mark A. | Towards a novel theranostics approach for AR-negative castration-resistant prostate cancer

Department for BioMedical Research (DBMR), Universität Bern, Bern
CHF 343 650 | 36 months | KFS-5754-02-2023

Weiss Tobias | Spatially resolved functional drug & immunotherapy profiling for novel combination therapies against glioblastoma

Department of Neurology, University Hospital Zurich, Zurich

CHF 291 450 | 36 months | KFS-5763-02-2023

Zucca Emanuele | IELSG52: integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma

IELSG, Institute of Oncology Research (IOR), Bellinzona

CHF 306 400 | 48 months | KFS-5778-02-2023

Clinical Research – patient-oriented

Chalandon Yves | A 3-cohort randomized study evaluating the place of new immunotherapeutic agents in frontline therapy of adult patients with acute lymphoblastic leukaemia (ALL) and the role of allogeneic haematopoietic stem cell transplantation (HSCT) in the phpos subgro

Service d'hématologie, Hôpitaux universitaires de Genève (HUG), Genève 14

CHF 371 600 | 48 months | KFS-5807-02-2023

Fierstra Jorn | A creative hypoxia-targeted fMRI approach for contrast free perfusion and tumour hypoxia measurements in patients with glioblastoma

Neurosurgery, University Hospital Zurich, Zürich

CHF 350 443 | 36 months | KFS-5983-08-2023

Hutter Gregor | First in human clinical trial with armoured anti-EGFRvIII-SGRP CARs against glioblastoma

Neurochirurgische Klinik, Universitätsspital Basel, Basel

CHF 375 000 | 48 months | KFS-5789-02-2023

Rentsch Cyrill A. | DISSECTION 2.0 - extended pelvic lymphadenectomy (ePLND) versus no ePLND during radical prostatectomy in high-risk, localized prostate cancer: a prospective randomized phase III study

Abteilung Urologie, Universitätsspital Basel, Basel

CHF 374 650 | 48 months | KFS-5775-02-2023

Riesterer Oliver | Analysis of clinical outcomes and modelling of the interaction between hyperthermia and radio(chemo)therapy in cancer patients

Radio-Onkologie-Zentrum KSA-KSB, Kantonsspital Aarau AG, Aarau

CHF 239 450 | 24 months | KFS-5746-02-2023

Todic Jelena | The robotic-assisted extended "Sistrunk" approach (RESA) for tumours of the upper aerodigestive tract with limited transoral access: a new surgical technique to improve laryngo-esophageal dysfunction free survival (LDFS)

Surgery, Central University Hospital of Vaud (CHUV), Lausanne

CHF 365 786 | 48 months | KFS-5920-08-2023

Wiest Reiner | Safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer (EBTC) undergoing standard of care chemotherapy: ABLATIO-BILICA

Universitätsklinik für Viszerale Chirurgie und Medizin (UVCN), Inselspital Bern, Bern

CHF 332 300 | 36 months | KFS-5812-02-2023

Zlobec Inti | Response prediction using spatial analysis of the dynamic tumour microenvironment following neoadjuvant treatment in localized rectal cancer

Institut für Pathologie, University of Bern, Bern
CHF 371 950 | 36 months | KFS-5786-02-2023

Health services research

Selby Kevin | Lausanne lung cancer screening pilot program

Département des Policliniques, Unisanté - Centre universitaire de médecine générale et santé publique - Lausanne, Lausanne
CHF 77 400 | 12 months | KFS-5909-08-2023

Psychosocial research

Chevallay Mickael | Assessing medical professionals and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: a study on gastric and esophageal cancer

Chirurgie viscérale, Hôpitaux universitaires de Genève (HUG), Genève
CHF 225 870 | 36 months | KFS-5986-08-2023

Schwappach David | Psychological harm as patient safety concern in advanced cancer care

Institute of Social and Preventive Medicine, Universität Bern, Bern
CHF 368 900 | 35 months | KFS-5738-02-2023

Waespe Nicolas | Improving cancer predisposition syndrome detection: a patient-centric approach

Pediatric Hematology/ Oncology, Inselspital Bern, Bern
CHF 327 364 | 36 months | KFS-5992-08-2023

Witt Claudia | eLearning of self-acupressure or a mindfulness technique to support symptom management in people with cancer: randomized controlled trials

Institute for Complementary and Integrative Medicine, University Hospital Zurich, Zürich
CHF 372 400 | 36 months | KFS-5723-02-2023

Fellowships

Bilfeld Gilles Maxime | Exploiting circulating tumour cells for the identification of immunotherapy responders

Department of Biology, ETH Zürich, Langnau am Albis
CHF 196 341 | 38 months | MD-PhD-5892-06-2023

Bürgin Damian Timo | The functional role of CD93 in multiple myeloma

Department of Biomedical Research, University of Bern, Bern
CHF 190 851 | 36 months | MD-PhD-5891-06-2023

Russkamp Norman Frederik | Development of TRAC-controlled HSPC-derived CAR T-cells for the treatment of haematological malignancies

Department of Hematology, Universitätsspital Basel, Zürich
CHF 126 000 | 24 months | KFS-5799-02-2023

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research